Effect of denosumab on bone mineral density in Japanese women with osteopenia treated with aromatase inhibitors for breast cancer: subgroup analyses of a Phase II study.

Conclusion: Twice-yearly treatment with denosumab was associated with increased BMD among Japanese women receiving adjuvant AI therapy, regardless of the baseline characteristics or skeletal site. PMID: 30022834 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/30022834?dopt=Abstract

Source: Clinical Genitourinary Cancer - July 21, 2018 Category: Cancer & Oncology Authors: Nakatsukasa K, Koyama H, Ouchi Y, Sakaguchi K, Fujita Y, Matsuda T, Kato M, Konishi E, Taguchi T Tags: Ther Clin Risk Manag Source Type: research